基于模型的呼气末正压滴定与传统实践在机械通气中的随机对照试验
CURE试验是一项单中心随机对照试验,纳入PaO2/FiO2≤200的中重度ARDS患者,比较基于模型最小呼吸系统弹性选择的PEEP与传统实践PEEP对氧合曲线下面积比值的影响。目标样本量320例,主要结局为动脉血氧合与吸入氧浓度随时间曲线下面积比值。
要点
- 针对PaO2/FiO2≤200的ARDS患者,比较模型化最小弹性PEEP与传统PEEP选择。
- 主要结局为氧合与FiO2随时间曲线下面积比值,次要结局包括无 ventilator 天数与死亡率。
- 该试验旨在验证患者个体化PEEP及实时决策支持在重症监护中的潜在获益。
核心结论
- CURE试验旨在验证基于模型最小弹性选择PEEP能否改善ARDS患者的临床结局。
研究设计与样本
- CURE试验为两臂随机对照试验,在新西兰基督城医院ICU单中心开展,目标样本量320例,最长3年。
- 纳入需要侵入性机械通气且PaO2/FiO2≤200的ARDS患者,采用压力控制通气,潮气量6-8 ml/kg。
关键数值与推荐
- 纳入标准:PaO2/FiO2≤200,符合柏林定义中重度ARDS标准。
- 主要结局:动脉血氧合与FiO2随时间曲线下面积比值。
- 次要结局包括机械通气时长、28天内无 ventilator 天数、ICU及住院时长、SpO2/FiO2曲线下面积、SpO2<88%事件数、呼吸力学与胸片评分变化、挽救治疗及住院和90天死亡率。
局限性
- 单中心研究,目标样本量320例,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Positive end-expiratory pressure (PEEP) at minimum respiratory elastance during mechanical ventilation (MV) in patients with acute respiratory distress syndrome (ARDS) may improve patient care and outcome. The Clinical utilisation of respiratory elastance (CURE) trial is a two-arm, randomised controlled trial (RCT) investigating the performance of PEEP selected at an objective, model-based minimal respiratory system elastance in patients with ARDS. METHODS AND DESIGN: The CURE RCT compares two groups of patients requiring invasive MV with a partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio ≤ 200; one criterion of the Berlin consensus definition of moderate (≤ 200) or severe (≤ 100) ARDS. All patients are ventilated using pressure controlled (bi-level) ventilation with tidal volume = 6-8 ml/kg. Patients randomised to the control group will have PEEP selected per standard practice (SPV). Patients randomised to the intervention will have PEEP selected based on a minimal elastance using a model-based computerised method. The CURE RCT is a single-centre trial in the intensive care unit (ICU) of Christchurch hospital, New Zealand, with a target sample size of 320 patients over a maximum of 3 years. The primary outcome is the area under the curve (AUC) ratio of arterial blood oxygenation to the fraction of inspired oxygen over time. Secondary outcomes include length of time of MV, ventilator-free days (VFD) up to 28 days, ICU and hospital length of stay, AUC of oxygen saturation (SpO2)/FiO2 during MV, number of desaturation events (SpO2 < 88%), changes in respiratory mechanics and chest x-ray index scores, rescue therapies (prone positioning, nitric oxide use, extracorporeal membrane oxygenation) and hospital and 90-day mortality. DISCUSSION: The CURE RCT is the first trial comparing significant clinical outcomes in patients with ARDS in whom PEEP is selected at minimum elastance using an objective model-based method able to quantify and consider both inter-patient and intra-patient variability. CURE aims to demonstrate the hypothesized benefit of patient-specific PEEP and attest to the significance of real-time monitoring and decision-support for MV in the critical care environment. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry, ACTRN12614001069640. Registered on 22 September 2014. (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366838&isReview=true) The CURE RCT clinical protocol and data usage has been granted by the New Zealand South Regional Ethics Committee (Reference number: 14/STH/132).
引用
- Kim KT, Morton S, Howe S, et al. Model-based PEEP titration versus standard practice in mechanical ventilation: a randomised controlled trial. Trials. 2020. PMID: 32007099. doi:10.1186/s13063-019-4035-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。